Michael Demurjian Sells 20,000 Shares of Tyme Technologies, Inc. (NASDAQ:TYME) Stock

Tyme Technologies, Inc. (NASDAQ:TYME) major shareholder Michael Demurjian sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, December 28th. The shares were sold at an average price of $1.12, for a total transaction of $22,400.00. Following the completion of the sale, the insider now directly owns 24,998,546 shares in the company, valued at approximately $27,998,371.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Michael Demurjian also recently made the following trade(s):

  • On Monday, December 21st, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.15, for a total transaction of $23,000.00.
  • On Monday, December 14th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.19, for a total transaction of $23,800.00.
  • On Monday, December 7th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.07, for a total transaction of $21,400.00.
  • On Monday, November 30th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.08, for a total transaction of $21,600.00.
  • On Monday, November 23rd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $0.93, for a total transaction of $18,600.00.
  • On Monday, November 2nd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $0.86, for a total transaction of $17,200.00.
  • On Monday, October 19th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.03, for a total transaction of $20,600.00.
  • On Friday, October 16th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.02, for a total transaction of $20,400.00.
  • On Wednesday, October 7th, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $1.00, for a total transaction of $20,000.00.
  • On Friday, October 2nd, Michael Demurjian sold 20,000 shares of Tyme Technologies stock. The shares were sold at an average price of $0.97, for a total transaction of $19,400.00.

Shares of TYME opened at $1.22 on Friday. The firm has a 50 day moving average price of $1.07 and a 200-day moving average price of $1.11. Tyme Technologies, Inc. has a fifty-two week low of $0.85 and a fifty-two week high of $2.04. The firm has a market cap of $158.81 million, a price-to-earnings ratio of -5.55 and a beta of 0.84.

Tyme Technologies (NASDAQ:TYME) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. Equities research analysts forecast that Tyme Technologies, Inc. will post -0.28 EPS for the current year.

Separately, Zacks Investment Research cut shares of Tyme Technologies from a “buy” rating to a “hold” rating in a research note on Friday, December 25th.

Hedge funds and other institutional investors have recently modified their holdings of the business. Lido Advisors LLC bought a new position in Tyme Technologies in the 2nd quarter worth $29,000. JPMorgan Chase & Co. grew its position in shares of Tyme Technologies by 78.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 39,474 shares of the company’s stock worth $37,000 after buying an additional 17,384 shares during the period. Jane Street Group LLC purchased a new stake in shares of Tyme Technologies in the 2nd quarter worth about $44,000. Goldman Sachs Group Inc. grew its position in shares of Tyme Technologies by 98.6% in the 2nd quarter. Goldman Sachs Group Inc. now owns 101,467 shares of the company’s stock worth $135,000 after buying an additional 50,384 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Tyme Technologies by 12.5% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 162,357 shares of the company’s stock worth $216,000 after buying an additional 17,994 shares during the period. Institutional investors and hedge funds own 14.00% of the company’s stock.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma.

Featured Story: Swap

Insider Buying and Selling by Quarter for Tyme Technologies (NASDAQ:TYME)

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.